What is Adagene?
Adagene Inc. is a biotechnology firm dedicated to the research, development, and production of innovative monoclonal antibody therapies targeting various cancers. Operating primarily within the People's Republic of China, the company leverages its scientific expertise to advance novel drug candidates through the clinical pipeline. Its strategic capital raises indicate a strong investor confidence in its therapeutic approach and market potential within the oncology sector.
How much funding has Adagene raised?
Adagene has raised a total of $320M across 6 funding rounds:
Series A
$8M
Series B
$28M
Series C
$50M
Series D
$69M
Stock Offering
$140M
Other Financing Round
$25M
Series A (2014): $8M with participation from Fidelity Biosciences, WuXi Venture Fund, and Fidelity Asia Growth
Series B (2016): $28M led by GP Healthcare Capital, New World TMT, F-Prime Capital (formerly Fidelity Biosciences), Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), and WuXi Corporate Venture Fund
Series C (2018): $50M supported by Gopher Asset Management, King Star Capital, Sequoia China, AVIC Trust, and New World TMT
Series D (2020): $69M featuring General Atlantic
Stock Issuance/Offering (2021): $140M, investors not publicly disclosed
Other Financing Round (2025): $25M with participation from Sanofi
Key Investors in Adagene
General Atlantic
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in sectors such as consumer, financial services, healthcare, life sciences, and technology.
Sequoia China
Sequoia Capital China is a prominent venture capital firm known for its investments in technology and healthcare sectors, actively supporting companies from early-stage to growth phases.
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on discovering, developing, and delivering medicines and vaccines.
What's next for Adagene?
The substantial enterprise-level capital Adagene has garnered, particularly the recent strategic investment, positions the company for accelerated growth and pipeline advancement. This financing is expected to fuel further research and development, potentially enabling Adagene to expand its therapeutic offerings, advance clinical trials, and solidify its market presence in the competitive biotechnology landscape. The company's trajectory suggests a focus on scaling its operations and bringing its innovative cancer treatments closer to market.
See full Adagene company page
